Zingg et al. discovered that H3K27me3 upregulation in melanoma resulted in transcriptional silencing of genes associated with immunogenicity and antigen presentation, which can synergistically inhibit melanoma growth through EZH2 inhibition using GSK503, alongside anti-CTLA-4 and IL-2 therapy. The gene discussed is IL2; the disease is melanoma.